Summary of Key Points Core Viewpoint - The company, Guoyao Modern, is undergoing a significant transaction involving the transfer of a 51% stake in Shanghai Modern Harsen Pharmaceutical Co., Ltd. The transaction is not classified as a major asset restructuring and is expected to impact the company's financial reporting structure post-completion [2][4]. Trading Information - As of July 31, 2025, Guoyao Modern's stock closed at 11.47 yuan, reflecting a decrease of 0.95%. The turnover rate was 2.33%, with a trading volume of 312,400 shares and a total transaction value of 361 million yuan [1]. - On the same day, the net outflow of main funds was 16.986 million yuan, accounting for 4.71% of the total transaction value. In contrast, retail funds saw a net inflow of 4.7 million yuan, representing 1.3% of the total transaction value [2][4]. Company Announcement - Guoyao Modern announced the public transfer of its 51% stake in Shanghai Modern Harsen Pharmaceutical Co., Ltd. at a base price of 155.192541 million yuan. The transaction does not constitute a major asset restructuring, and the details regarding the transaction counterpart, price, and timing are yet to be determined [2][4]. - As of April 30, 2025, Shanghai Modern Harsen reported total assets of 339.1778 million yuan, total liabilities of 187.15 million yuan, and owner’s equity of 152.0278 million yuan. The revenue for the first four months of 2025 was 100.7613 million yuan, with a net loss of 19.898 million yuan [2]. - The assessed value of the total equity of Shanghai Modern Harsen is 304.2991 million yuan, indicating a value increase of 100.16% [2].

Core Viewpoint - Shanghai Modern Pharmaceutical Co., Ltd. is publicly transferring 51% equity of its subsidiary, Shanghai Modern Harsen (Shangqiu) Pharmaceutical Co., Ltd., with a base price of RMB 155.192541 million, aiming to optimize resource allocation and improve operational efficiency [2][4]. Group 1: Transaction Overview - The company announced the public transfer of 51% equity of its subsidiary on July 30, 2025, with a base price set at RMB 155.192541 million [2][4]. - The transaction does not constitute a major asset restructuring and is not currently classified as a related party transaction [3][4]. - The transfer aims to enhance the company's strategic focus and asset efficiency, as the subsidiary has been underperforming since 2021 [12]. Group 2: Target Company Information - The target company, Shanghai Modern Harsen (Shangqiu) Pharmaceutical Co., Ltd., was established on November 12, 1999, with a registered capital of RMB 83.29 million [6]. - The company operates in the production and sales of pharmaceuticals, disinfectants, health foods, and other related products [7]. - As of April 30, 2025, the net assets of the target company were valued at RMB 152.0278 million, with a total equity valuation of RMB 304.2991 million, reflecting a 100.16% increase in value [9]. Group 3: Financial Impact and Future Steps - The completion of the equity transfer will result in the subsidiary no longer being included in the company's consolidated financial statements, potentially impacting the company's financial performance for 2025 [12]. - The specific details regarding the buyer and final transaction price remain undetermined, and the company will disclose further information as the transaction progresses [11][12].

Transaction Overview - Shanghai Modern Pharmaceutical Co., Ltd. plans to publicly transfer 51% equity of its subsidiary, Shanghai Modern Harsen (Shangqiu) Pharmaceutical Co., Ltd. (referred to as Guoyao Harsen), with a base price of RMB 155.192541 million [1][2] - The transaction does not constitute a major asset restructuring and is subject to uncertainties regarding the transaction object, price, and timing [1][2] Transaction Details - The transfer will be conducted through the Shanghai United Assets and Equity Exchange, and the final buyer is yet to be determined [2] - Guoyao Harsen was established on November 12, 1999, with a registered capital of RMB 83.29 million, and its business scope includes the production and sale of pharmaceuticals, disinfectants, health foods, and more [2] Financial Performance - As of April 30, 2025, Guoyao Harsen reported total assets of RMB 339.1778 million, total liabilities of RMB 187.15 million, and a net loss of RMB 19.898 million [3][4] - The net asset value of Guoyao Harsen was RMB 152.0278 million, with an assessed value of RMB 304.2991 million, indicating a 100.16% increase in value [4] Strategic Implications - The divestiture aims to enhance the company's focus on core areas, optimize asset structure, and improve operational efficiency, as Guoyao Harsen has faced continuous operational pressure and losses since 2021 [5] - Post-transaction, Guoyao Harsen will no longer be included in the company's consolidated financial statements, aligning with the interests of the company and its shareholders [5]

（文章来源：证券日报） 证券日报网讯 7月30日晚间，国药现代发布公告称，公司于2025年7月30日在上海联合产权交易所公开 挂牌，转让所持有的上海现代哈森（商丘）药业有限公司（简称"国药哈森"）51%股权，挂牌底价为人 民币15，519.2541万元。上述事项已经公司总裁办公会审议通过，并已获得中国医药集团有限公司批 复。根据《上海证券交易所股票上市规则》及公司《章程》，该事项目前无需提交董事会审议。 ...

证券代码：600420 证券简称：国药现代 公告编号：2025-059 上海现代制药股份有限公司 关于公开挂牌转让控股子公司股权的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海现代制药股份有限公司（以下简称公司）于 2025 年 7 月 30 日在上 海联合产权交易所公开挂牌，转让所持有的上海现代哈森（商丘）药业有限公司 （以下简称国药哈森）51%股权，挂牌底价为人民币 15,519.2541 万元。 本次交易不构成重大资产重组。 本次交易的交易对象、交易价格和交易时间尚未确定，交易成功与否尚 存在不确定性，目前暂不构成关联交易。公司将根据本次交易的后续进展情况， 按照有关规定及时履行信息披露义务，敬请广大投资者注意投资风险。 一、交易概述 2025 年 7 月 1 日，公司披露了《关于拟公开转让控股子公司股权预挂牌的 提示性公告》，为推进实施公司中长期战略规划，优化资源配置，提高公司资产 的运营效率，公司拟公开挂牌转让控股子公司国药哈森 51%股权（详见公司 2025-55 号公告）。 202 ...

金融界消息 截至2025年7月29日收盘，国药现代（600420）报收于11.36元，上涨1.07%，换手率 1.45%，成交量19.49万手，成交金额2.20亿元。 资金流向方面，今日主力资金净流入1962.14万元，占比成交额8.91%。其中，超大单净流入520.72万 元、占成交额2.36%，大单净流入1441.42万元、占成交额6.54%，中单净流出流入217.09万元、占成交 额0.99%，小单净流出2179.23万元、占成交额9.89%。 通过天眼查大数据分析，上海现代制药股份有限公司共对外投资了23家企业，参与招投标项目5000次， 知识产权方面有商标信息113条，专利信息137条，此外企业还拥有行政许可245个。 来源：金融界 国药现代最新一期业绩显示，截至2025一季报，公司营业总收入26.07亿元、同比减少16.54%，归属净 利润3.61亿元，同比增长9.10%，扣非净利润3.46亿元，同比增长6.24%，流动比率3.317、速动比率 2.682、资产负债率18.54%。 天眼查商业履历信息显示，上海现代制药股份有限公司，成立于1996年，位于上海市，是一家以从事医 药制造业为主的企业。 ...

Group 1 - The fentanyl concept index declined by 0.88%, ranking among the top declines in the concept sector as of July 29 [1] - Within the fentanyl sector, companies such as Botao Bio, Enhua Pharmaceutical, and Wanfu Bio experienced significant declines, while three companies, including China National Pharmaceutical Modern, Lingrui Pharmaceutical, and Renfu Pharmaceutical, saw slight increases of 1.07%, 0.17%, and 0.09% respectively [1] Group 2 - The fentanyl concept sector experienced a net outflow of 80 million yuan in capital today, with six stocks seeing net outflows, and five stocks with outflows exceeding 10 million yuan [2] - Renfu Pharmaceutical had the highest net outflow of 18.1651 million yuan, followed by Dongfang Bio, Enhua Pharmaceutical, and Wanfu Bio with net outflows of 16.8542 million yuan, 16.6752 million yuan, and 15.9620 million yuan respectively [2] - The top net inflow stocks in the fentanyl concept sector included China National Pharmaceutical Modern and China National Pharmaceutical, with net inflows of 9.5225 million yuan and 1.2608 million yuan respectively [2]

上海现代制药股份有限公司 关于下属子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）下属子公司国药集团容 生制药有限公司（以下简称国药容生）、国药一心制药有限公司（以下简称国药 一心）分别收到国家药品监督管理局核准签发的《药品注册证书》。现将相关情 况公告如下： 一、盐酸咪达普利片 （一）药品基本信息 药品名称：盐酸咪达普利片 剂型：片剂 规格：5mg 证券代码：600420 证券简称：国药现代 公告编号：2025-058 注册分类：化学药品 4 类 证书编号：2025S02225 （二）药品研发及市场情况 药品批准文号：国药准字 H20254897 上市许可持有人：国药集团容生制药有限公司 药品生产企业：国药集团容生制药有限公司 申请事项：药品注册（境内生产） 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 盐酸咪达普利片适用于治疗：1、原发性高血压；2、肾实质性病变所致继发 性 ...

Core Viewpoint - China National Pharmaceutical Group Modern (国药现代) announced that its subsidiaries, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd. and China National Pharmaceutical Group Yixin Pharmaceutical Co., Ltd., have received drug registration certificates from the National Medical Products Administration for two new drugs [1] Group 1: Drug Approvals - China National Pharmaceutical Group Rongsheng's drug, named Midapril Hydrochloride Tablets, is a tablet formulation with a specification of 5mg, classified as a Class 4 chemical drug, with registration certificate number 2025S02225 and approval number H20254897 [1] - China National Pharmaceutical Group Yixin's drug, named Calcium Leucovorin Injection, is an injectable formulation with a specification of 10ml:0.1g (calculated as C H N O), also classified as a Class 4 chemical drug, with registration certificate number 2025S02226 and approval number H20254898 [1]

Group 1 - The event showcased four Shandong enterprises as examples of transitioning from a "manufacturing province" to a "brand strong province" [1][3] - The companies emphasized "chain development" to enhance industrial competitiveness, with Furuida Bio focusing on a full industry chain in the beauty sector, holding over 170 patents and participating in over 30 national standards [3][4] - Hisense Group is expanding from home appliances to high-end industries like semiconductors and smart energy, planning to drive investment or expansion in 25 related enterprises by 2024 [3][4] Group 2 - Furuida Bio aims to create a dual beauty ecosystem through its brand matrix, with a planned output value of 5 billion yuan for its innovation park in 2024 [4] - Hisense is innovating for overseas markets, exemplified by a custom black mirror refrigerator for South Africa, and has maintained the second position in global TV shipments for three consecutive years [4] - Shandong has cultivated 427 brands through systematic initiatives, with 80% of major technology projects in 2024 being undertaken by enterprises in collaboration with universities [4]